TTrialPathMatch Me to Trials
← Back to trials
RecruitingPediatric Osteosarcoma

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

Eligible age

Up to 21 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to assess the safety, feasibility, and effectiveness of a consolidative B7-H3 CAR T cell therapy in patients with newly diagnosed high-risk osteosarcoma who have undergone upfront standard chemotherapy. Primary Objectives: \- To evaluate 1-year RFS from the time of SJCARB7H3-41BBL infusion for patients with newly diagnosed metastatic osteosarcoma who received standard chemotherapy. Secondary Objectives: * To evaluate the OS from time of SJCARB7H3-41BBL infusion for patients with newly diagnosed metastatic osteosarcoma who received standard chemotherapy. * To evaluate the feasibility of delivering SJCARB7H3-41BBL at the end of standard therapy in patients with newly diagnosed metastatic osteosarcoma. * To describe the safety of autologous SJCARB7H3-41BBL therapy when delivered at the end of standard therapy in patients with newly diagnosed metastatic osteosarcoma.

Sponsor: St. Jude Children's Research Hospital

You may qualify if…

  • ✓ 1. Participant and/or legally authorized representative has signed the Informed Consent Form for this study
  • ✓ 2. Prior cancer therapy:
  • ✓ Regimen A only: Completed all planned cycles of consolidation therapy between 14-28 days prior.
  • ✓ Regimen B only: has completed all planned cycles of consolidation chemotherapy at least 14 days prior and if clinically indicated, participant has undergone pulmonary metastasectomy. They must have recovered from any surgical complications with no ongoing sequelae of category 2 or higher by the Clavien-Dindo classification system and less than 6 weeks must have passed from time of pulmonary metastasectomy.
  • ✓ 3. No evidence of progressive disease since enrolled on study
  • ✓ 4. Lansky performance status score of ≥ 50 for participants \<16 years of age or Karnofsky score ≥ 50 for participants ≥ 16 years. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for purposes of assessing performance status
  • ✓ 5. Adequate organ function as indicated by:
  • ✓ Renal: Serum creatinine ≤ 1.5 X the upper limit of normal (ULN) based on enrollment eligibility table.

You may not qualify if…

  • ✕ 1. Major surgical adverse event related to the primary tumor local control defined as Clavien-Dindo category 3 requiring ongoing wound care.
  • ✕ 2. Evidence of clinically significant encephalopathy/new focal neurologic deficits.
  • ✕ 3. Presence of active severe infection, defined as:
  • ✕ positive blood culture within 48 hours of enrollment, OR
  • ✕ fever above 38.2° C, AND clinical signs of infection within 48 hours of enrollment
  • ✕ 4. Participant has received prior disease-directed therapy other than 1st line therapy with methotrexate, an anthracycline, and a platinum and local control surgery
  • ✕ Regimen B only - okay to have undergone initial pulmonary metastasectomy
  • ✕ 5. Pregnant or breastfeeding

Where it's recruiting

Tennessee

Memphis

Source: ClinicalTrials.gov · NCT07428993 · last updated 2026-11-03

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Up · TrialPath